‘Recovery on the Horizon,’ Says Morgan Stanley Analyst on UnitedHealth Stock (UNH)

UnitedHealth (UNH) stock is recovering from a significant 2025 decline, buoyed by an upbeat Medicare Star Ratings update and renewed investor confidence. Morgan Stanley analyst Erin Wright reiterated an Overweight rating, citing management's conviction in profit recovery across Medicare Advantage (MA) and Optum Health. Wright projects MA pre-tax margins to expand from 2.0-2.5% in 2025 to 2.5-3.0% in 2026, driven by strategic plan exits and an anticipated increase to 78% of MA members in 4-star or higher plans by 2026. This improved outlook suggests UNH could achieve 6-8% pre-tax margins by 2028, aligning with a broader Wall Street 'Strong Buy' consensus, though the average price target currently implies a slight downside.

Analysis

UnitedHealth (UNH) is presenting a potential turnaround narrative after a substantial 37% stock price decline in 2025, with recent performance showing a 4% recovery over the last three months. This nascent rebound is supported by a positive update on its Medicare Star Ratings and a reaffirmed Overweight rating from Morgan Stanley, which holds a $325 price target. The core of the bull thesis rests on management's conviction in a profit recovery, driven by improvements in both Medicare Advantage (MA) and Optum Health. Specifically, MA pre-tax margins are projected to expand from 2.0–2.5% in 2025 to 2.5–3.0% in 2026. A key strategic element is the planned exit from contracts covering approximately 600,000 members, a move viewed as a margin-accretive strategy to shed less profitable business. Further bolstering this outlook is the anticipated improvement in Medicare Star Ratings, with projections showing 78% of MA members will be in 4-star or higher-rated plans by 2026, up from 71% currently. Despite this detailed positive outlook and a 'Strong Buy' consensus from Wall Street analysts, a notable disconnect exists, as the average price target of $322.28 implies a 7.37% downside from current levels, suggesting potential valuation concerns or that the market has already priced in some of the recovery.

Key Decisions for Investors

• Investors with a long-term horizon may consider the current situation a turnaround opportunity, focusing on the projected multi-year margin expansion in Medicare Advantage and the long-term potential for 6-8% pre-tax margins by 2028.
• It is critical to monitor the execution of the company's strategy, particularly the net financial impact of shedding 600,000 members and the actualization of improved Medicare Star Ratings to 78% in 4-star+ plans.
• Given the average analyst price target implies a 7.37% downside despite a 'Strong Buy' consensus, investors should be cautious of potential near-term valuation headwinds and weigh the bullish fundamental outlook against the risk that the recovery is already reflected in the current stock price.